AU2017363313B2 - Inhibitors of interleukin-1 receptor-associated kinases and uses thereof - Google Patents
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof Download PDFInfo
- Publication number
- AU2017363313B2 AU2017363313B2 AU2017363313A AU2017363313A AU2017363313B2 AU 2017363313 B2 AU2017363313 B2 AU 2017363313B2 AU 2017363313 A AU2017363313 A AU 2017363313A AU 2017363313 A AU2017363313 A AU 2017363313A AU 2017363313 B2 AU2017363313 B2 AU 2017363313B2
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- alkyl
- certain embodiments
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425503P | 2016-11-22 | 2016-11-22 | |
| US62/425,503 | 2016-11-22 | ||
| PCT/US2017/063139 WO2018098367A1 (en) | 2016-11-22 | 2017-11-22 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017363313A1 AU2017363313A1 (en) | 2019-05-23 |
| AU2017363313B2 true AU2017363313B2 (en) | 2021-06-24 |
Family
ID=60703094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017363313A Active AU2017363313B2 (en) | 2016-11-22 | 2017-11-22 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10975055B2 (enExample) |
| EP (1) | EP3544970B1 (enExample) |
| JP (1) | JP7308146B2 (enExample) |
| AU (1) | AU2017363313B2 (enExample) |
| CA (1) | CA3042731A1 (enExample) |
| WO (1) | WO2018098367A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4624467A2 (en) | 2017-09-22 | 2025-10-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020081572A1 (en) * | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
| KR102891608B1 (ko) | 2018-11-30 | 2025-11-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| KR20220006139A (ko) | 2019-04-05 | 2022-01-14 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| CA3162470A1 (en) * | 2019-11-22 | 2021-05-27 | The Regents Of The University Of California | Caspase 6 inhibitors and uses thereof |
| EP4074697B1 (en) * | 2019-12-03 | 2025-05-21 | Samjin Pharmaceutical Co., Ltd. | Novel adamantane derivatives as inhibitors of focal adhesion kinase |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021133920A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| IL296451A (en) | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | Mdm2 degraders and uses thereof |
| US20240043405A1 (en) * | 2020-03-23 | 2024-02-08 | Dana-Farber Cancer Institute, Inc. | Potent and selective irreversible inhibitors of irak1 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US20230295146A1 (en) * | 2020-07-24 | 2023-09-21 | The University Of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| MX2023009527A (es) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics Inc | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. |
| EP4308096A4 (en) * | 2021-03-17 | 2025-04-16 | Merck Sharp & Dohme LLC | Heteroaroylamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| IL312397A (en) | 2021-10-29 | 2024-06-01 | Kymera Therapeutics Inc | IRAK4 subunits and their synthesis |
| US12091411B2 (en) | 2022-01-31 | 2024-09-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014058691A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| WO2015106058A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Patent Gmbh | Pyrimidine pyrazolyl derivatives and their use as irak inhibitors |
| WO2016081679A1 (en) * | 2014-11-20 | 2016-05-26 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (zh) * | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| CA2932353A1 (en) * | 2013-12-13 | 2015-06-18 | Steven P. Treon | Methods to treat lymphoplasmacytic lymphoma |
| HRP20190039T1 (hr) * | 2014-04-04 | 2019-03-08 | Syros Pharmaceuticals, Inc. | Inhibitori ciklin-ovisne kinaze 7 (cdk7) |
-
2017
- 2017-11-22 AU AU2017363313A patent/AU2017363313B2/en active Active
- 2017-11-22 CA CA3042731A patent/CA3042731A1/en active Pending
- 2017-11-22 WO PCT/US2017/063139 patent/WO2018098367A1/en not_active Ceased
- 2017-11-22 US US16/462,200 patent/US10975055B2/en active Active
- 2017-11-22 EP EP17817469.4A patent/EP3544970B1/en active Active
- 2017-11-22 JP JP2019527449A patent/JP7308146B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014058691A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| WO2015106058A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Patent Gmbh | Pyrimidine pyrazolyl derivatives and their use as irak inhibitors |
| WO2016081679A1 (en) * | 2014-11-20 | 2016-05-26 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190276426A1 (en) | 2019-09-12 |
| WO2018098367A1 (en) | 2018-05-31 |
| US20200299257A9 (en) | 2020-09-24 |
| AU2017363313A1 (en) | 2019-05-23 |
| EP3544970B1 (en) | 2021-11-17 |
| US10975055B2 (en) | 2021-04-13 |
| JP2019535759A (ja) | 2019-12-12 |
| JP7308146B2 (ja) | 2023-07-13 |
| EP3544970A1 (en) | 2019-10-02 |
| CA3042731A1 (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017363313B2 (en) | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | |
| JP7472026B2 (ja) | 選択的なタンパク質分解を誘導するための低分子およびその使用法 | |
| AU2017363307B2 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| US12415816B2 (en) | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| AU2020263390B2 (en) | Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| JP7675070B2 (ja) | 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体 | |
| AU2020301399B2 (en) | HCK degraders and uses thereof | |
| EP3876930A1 (en) | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| WO2017027845A1 (en) | Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases | |
| US20230058545A1 (en) | Hck as a therapeutic target in myd88 mutated diseases | |
| AU2019318046B2 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| US20230339865A1 (en) | Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |